Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.0K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.0K
Acute Pharyngitis01:30

Acute Pharyngitis

4.3K
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
4.3K
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

1.3K
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.3K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

1.0K
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.0K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

507
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
507

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026
Same author

Toolkit for multistate disease progression simulation and treatment decision-making aid.

BMC medical research methodology·2026
Same author

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Haematologica·2026
Same author

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Cardio-oncology (London, England)·2026
Same author

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

Leukemia·2026
Same author

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Blood advances·2026

Video Experimental Relacionado

Updated: Feb 7, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K

Leucemia mieloide aguda

Nicholas J Short1, Michael E Rytting2, Jorge E Cortes1

  • 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lancet (London, England)
|August 7, 2018
PubMed
Resumen

Los avances recientes ofrecen nuevos tratamientos para la leucemia mieloide aguda (LMA) y una mejor evaluación del riesgo. Sin embargo, los resultados de los pacientes siguen siendo pobres, lo que requiere ensayos clínicos para nuevas terapias y combinaciones para mejorar aún más las tasas de supervivencia.

Más Videos Relacionados

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.6K

Videos de Experimentos Relacionados

Last Updated: Feb 7, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.6K

Área de la Ciencia:

  • Hematología
  • En el campo de la oncología
  • La genómica

Sus antecedentes:

  • La leucemia mieloide aguda (LMA) ha tenido un progreso terapéutico limitado durante décadas.
  • Los últimos años (desde 2017) muestran avances significativos en las aprobaciones de medicamentos para la LMA y el entendimiento biológico.
  • A pesar del progreso, los resultados de los pacientes con LMA siguen siendo insatisfactorios, con altas tasas de mortalidad.

Objetivo del estudio:

  • Para resumir los recientes avances terapéuticos y biológicos en la leucemia mieloide aguda.
  • Resaltar la necesidad de continuar la investigación y los ensayos clínicos en el tratamiento de la LMA.

Principales métodos:

  • Revisión de las recientes aprobaciones regulatorias de medicamentos para la LMA.
  • Análisis de la evolución de la comprensión de la biología de la LMA y la arquitectura genómica.
  • Examen de las directrices actualizadas de estratificación del riesgo que incorporan aberraciones moleculares.

Principales resultados:

  • Se han aprobado múltiples medicamentos nuevos para el tratamiento de la LMA desde 2017.
  • Las estrategias de evaluación de riesgos refinadas ahora incluyen aberraciones moleculares para el manejo personalizado.
  • Más de la mitad de los pacientes con LMA todavía sucumben a la enfermedad, lo que indica necesidades no satisfechas.

Conclusiones:

  • El panorama del tratamiento de la leucemia mieloide aguda ha evolucionado rápidamente con nuevas terapias y herramientas de diagnóstico.
  • Una mejor comprensión de la genómica de la LMA ayuda en las estrategias adaptadas al riesgo.
  • La participación en ensayos clínicos es crucial para desarrollar nuevas combinaciones y mejorar la supervivencia de los pacientes con LMA.